Russian Military Medical Academy ReportsRussian Military Medical Academy Reports2713-23152713-2323Eco-Vector3381910.17816/rmmar33819Research ArticleCOMPARISON OF EFFICIENCY OF METHYLENE BLUE DRUGS FOR VISUALIZATIONOF LYMPHOTOUS WAYS IN THE EXPERIMENTKovalenkoV V-BarinovO V-FufaevE E-DmitrochenkoI V-KurakevichI V-OvcharenkoA P-S. M. Kirov Military Medical Academy of the Russian Defense MinistryBranch N 1 "439 Military Hospital" of the Russian Defense Ministry15032020391606520042020Copyright © 2020, Kovalenko V.V., Barinov O.V., Fufaev E.E., Dmitrochenko I.V., Kurakevich I.V., Ovcharenko A.P.2020Objective. compare and evaluate the effectiveness of using methylene blue solutions to visualize lymphatic outflow pathways in laboratory animals (outbred rat). Materials and methods. In the experiment were used 16 female outbred rats aged about 40 days with an initial body weight of 180-220 g contained in standard vivarium conditions. For anesthesia was used “Zolazepam“ (Zoletil®100). Animals were randomized into 2 groups - 8 in each. The first group was injected subcutaneously in the left thigh with a 1% aqueous solution of methylene blue, the second group - solution of methylene blue with human serum albumin. Depending on the time of exposure, animals were divided randomly into 4 subgroups - 15, 30, 45 and 60 minutes. There was evaluated the effectiveness of marking the pathways of lymph outflow from the injection site. Results. As a result of the study, it was demonstrated that the use of a 1% methylene blue solution allows visualizing of the lymphatic outflow paths during drug exposure for 30 minutes. Staining of the lymph nodes of the next order occurs with an increase in exposure time. A solution of methylene blue in combination with human serum albumin stains the first node in the lymph drainage path 30 minutes after administration. The drug is characterized by slow migration from the first order lymph nodes (>60 minutes). Conclusion. The use of methylene blue solution in combination with serum albumin characterized by slow migration from the first order lymph nodes, which makes its use preferable in surgical interventions (8 figs, 1 table, bibliography: 14 refs).human serum albuminmethylene bluemicrometastasisnon-small cell lung cancerN-stagingsentinel lymph nodesignal lymph nodeметиленовый синиймикрометастазнемелкоклеточный рак легкогоN-стадированиесигнальный лимфатический узелсторожевой лимфатический узелчеловеческий сывороточный альбумин[Siegel R. L. Cancer statistics. CA Cancer J. Clinic. 2019; 69 (1): 7-34.][Bray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394-424.][Bille A. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur. J. Cardiothorac. Surg. 2017; 51 (4): 674-79.][Akopov A. L., Papayan G. V., Chistyakov I. V. Intraoperative determination of “signal” lymph nodes using an infrared imaging system for locally advanced non-small cell lung cancer. Vestnik khirurgii imeni I. I. Grekova. 2015; 174 (4): 13-7.][Amiraliev A. M., Pikin O. V., Ryabov A. B. Segmentectomy in patients with malignant neoplasms of the lungs. P. A. Herzen Journal of Oncology. 2017; 6 (5): 87-95. Russian (Амиралиев А. М., Пикин О. В., Рябов А. Б. Сегментэктомия у больных со злокачественными новообразованиями легких. Онкология. Журнал им. П. А. Герцена. 2017; 6 (5): 87-95).][Usman A. M., Miller J., Peirson L., Fitzpatrick-Lewis D., Kenny M., Sherifali D., Parminder R. Screening for lung cancer: A systematic review and meta-analysis. Prev. Med. 2016; 89 (3): 301-14.][Silvestri G. A., Gonzalez A. V., Jantz M. A. , Margolis M. L., Gould M. K., Tanoue L. T., Harris L. J., Detterbeck F. C. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5): 211-50.][Ettinger D. S., Wood D. E., Aisner D. L. , Akerley W., Bauman J. R., Bharat A., Bruno D. S., Chang J. Y., Chirieac L. R. Non-Small Cell Lung Cancer, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2019; 15 (4): 504-35.][Manikhas G. M., Martynyuk V. V., Zin’kevich M. V. Biopsy of the signal lymph node with melanoma of the skin of the limbs and trunk. Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii imeni I. I. Mechnikova. 2008; 1: 107-10. Russian (Манихас Г. М., Мартынюк В. В., Зинькевич М. В. Биопсия сигнального лимфатического узла при меланоме кожи конечностей и туловища. Вестник Санкт-Петербургской государственной медицинской академии имени И. И. Мечникова. 2008; 1: 107-10).][Ismagilov A. Kh., Asnina N. G., Azarov G. A. Signal lymph node biopsy: history and modernity. Opukholi zhenskoy reproduktivnoy sistemy. 2018; 14 (1): 38-46. Russian (Исмагилов А. Х., Аснина Н. Г., Азаров Г. А. Биопсия сигнальных лимфатических узлов: история и современность. Опухоли женской репродуктивной системы. 2018; 14 (1): 38-46).][Tiff et O., Perrot J. L., Gentil-Perret A., Prevot N., Dubois F., Alamrtine E., Cambazard F. Sentinel lymph node detection in primary melanoma with preoperative dynamic lymphoscintigraphy and intraoperative γ probe guidance. Br. J. Surg. 2004; 91(7): 886-92.][Wishart G. C., Loh S.-W., Jones L., Benson J. R. A feasibility study (ICG-10) of indocyanine green (ICG) fl uorescence mapping for sentinel lymph node detection in early breast cancer. Eur. J. Surg. Oncol. 2012; 38 (8): 651-6.][Hachey K. J., Colson Y. L. Current Innovations in Sentinel Lymph Node Mapping for the Staging and Treatment of Resectable Lung Cancer. Semin. Thorac. Cardiovasc. Surg. 2014; 26 (3): 201-9.][Treuting P. M., Dintzis S. M., Montine K. Hematopoietic and Lymphoid Tissues. In: Comparative Anatomy and Histology. Second Edition. A Mouse, Rat, and Human Atlas. London, UK: Academic Press, Elsevier Publisher; 2018: 365-401.]